These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 33533060)

  • 1. Isoelectric point determination by imaged CIEF of commercially available SARS-CoV-2 proteins and the hACE2 receptor.
    Krebs F; Scheller C; Grove-Heike K; Pohl L; Wätzig H
    Electrophoresis; 2021 Mar; 42(6):687-692. PubMed ID: 33533060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.
    Maas MN; Hintzen JCJ; Löffler PMG; Mecinović J
    Chem Commun (Camb); 2021 Apr; 57(26):3283-3286. PubMed ID: 33651072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of molecular interaction, physicochemical parameters and conserved pattern of SARS-CoV-2 Spike RBD and hACE2: in silico and molecular dynamics approach.
    Chakraborty C; Sharma AR; Mallick B; Bhattacharya M; Sharma G; Lee SS
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1708-1723. PubMed ID: 33629340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
    Choudhury A; Mukherjee S
    J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors.
    Rodriguez JH; Gupta A
    Sci Rep; 2021 Jan; 11(1):1156. PubMed ID: 33441985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific characterization of SARS-CoV-2 spike glycoprotein receptor-binding domain.
    Antonopoulos A; Broome S; Sharov V; Ziegenfuss C; Easton RL; Panico M; Dell A; Morris HR; Haslam SM
    Glycobiology; 2021 Apr; 31(3):181-187. PubMed ID: 32886791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 omicron RBD forms a weaker binding affinity to hACE2 compared to Delta RBD in
    Le HT; Tran LH; Phung HTT
    J Biomol Struct Dyn; 2024 May; 42(8):4087-4096. PubMed ID: 37345564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An efficient system to generate truncated human angiotensin converting enzyme 2 (hACE2) capable of binding RBD and spike protein of SARS-CoV2.
    Gao X; Liang K; Mei S; Peng S; Vong EG; Zhan J
    Protein Expr Purif; 2021 Aug; 184():105889. PubMed ID: 33852951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
    Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
    F1000Res; 2020; 9():576. PubMed ID: 32802318
    [No Abstract]   [Full Text] [Related]  

  • 11. SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets.
    Raghuvamsi PV; Tulsian NK; Samsudin F; Qian X; Purushotorman K; Yue G; Kozma MM; Hwa WY; Lescar J; Bond PJ; MacAry PA; Anand GS
    Elife; 2021 Feb; 10():. PubMed ID: 33554856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingerprinting trimeric SARS-CoV-2 RBD by capillary isoelectric focusing with whole-column imaging detection.
    Du J; Wu G; Chen Q; Yu C; Xu G; Liu A; Wang L
    Anal Biochem; 2023 Feb; 663():115034. PubMed ID: 36586502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2.
    Shajahan A; Archer-Hartmann S; Supekar NT; Gleinich AS; Heiss C; Azadi P
    Glycobiology; 2021 May; 31(4):410-424. PubMed ID: 33135055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.
    Rui L; Haonan L; Wanyi C
    Biophys Chem; 2020 Dec; 267():106472. PubMed ID: 32916377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of binding ability prediction between spike protein and human ACE2 reveals the adaptive strategy of SARS-CoV-2 in humans.
    Xue X; Shi J; Xu H; Qin Y; Yang Z; Feng S; Liu D; Jian L; Hua L; Wang Y; Zhang Q; Huang X; Zhang X; Li X; Chen C; Guo J; Tang W; Liu J
    Sci Rep; 2021 Feb; 11(1):3187. PubMed ID: 33542420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of An 84-bp Deletion of the Receptor-Binding Domain on the ACE2 Binding Affinity of the SARS-CoV-2 Spike Protein: An In Silico Analysis.
    Kemenesi G; Tóth GE; Bajusz D; Keserű GM; Terhes G; Burián K; Zeghbib S; Somogyi BA; Jakab F
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics and electrostatics define an allosteric druggable site within the receptor-binding domain of SARS-CoV-2 spike protein.
    Bhattacharjee S; Bhattacharyya R; Sengupta J
    FEBS Lett; 2021 Feb; 595(4):442-451. PubMed ID: 33449359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AI-based spectroscopic monitoring of real-time interactions between SARS-CoV-2 and human ACE2.
    Ye S; Zhang G; Jiang J
    Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34185681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).
    Egieyeh S; Egieyeh E; Malan S; Christofells A; Fielding B
    PLoS One; 2021; 16(1):e0245258. PubMed ID: 33417604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.